NasdaqGS:ZYMEBiotechs
Zymeworks (ZYME): Evaluating Valuation After Global Approvals for Zanidatamab and Pipeline Progress
When a biotech like Zymeworks (ZYME) makes headlines, investors tend to perk up. The company's recent announcement of receiving regulatory approvals for its novel dual HER2-targeted bispecific antibody, zanidatamab, across the U.S., China, and Europe signals a significant milestone. While discontinuing clinical development for ZW171 might have raised some eyebrows, the spotlight remains firmly on zanidatamab’s potential in the cancer therapy space.
These pipeline and approval updates come at...